Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Business Wire

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
From Delcath Systems, Inc.
Via Business Wire
Tickers DCTH
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
From Delcath Systems, Inc.
Via Business Wire
Tickers DCTH
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
From Aurion Biotech
Via Business Wire
13th Annual Energy Day Festival Sparks STEM Interest Among Houston Students
From Consumer Energy Education Foundation
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
Snap Inc. Deadline: Rosen Law Firm Urges Snap Inc. (NYSE: SNAP) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Tickers SNAP
Infrrd Announces the Official Launch of Ally: The First Agentic AI Workforce for Mortgage Auditing
From Infrrd
Via Business Wire
University of Phoenix College of Social and Behavioral Sciences Leadership Publishes White Paper on Trauma-Informed Education
From University of Phoenix
Via Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
From Deciphera Pharmaceuticals Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
From Genmab
Via Business Wire
Tickers GMAB
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
From Salubris Biotherapeutics, Inc.
Via Business Wire
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
CORRECTING and REPLACING Alliant Insurance Services Expands Transportation Risk and Cross-Border Expertise in Texas through Strategic Acquisition and Key Hires
From Alliant Insurance Services
Via Business Wire
Light & Wonder Statement on NV Legal Proceedings
From Light & Wonder, Inc.
Via Business Wire
Tickers ASX:LNW LNW
Typhoon Recovery: U-Haul Offers 30 Days Free Storage across Alaska
From U-Haul Holding Company
Via Business Wire
Tickers UHAL
Kolibri Global Energy Inc. Provides Update Regarding Information Circular Disclosure
From Kolibri Global Energy Inc.
Via Business Wire
Tickers KGEI TSX:KEI
Securities Fraud Investigation Into MoonLake Immunotherapeutics (MLTX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Tickers MLTX
MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Tickers MLTX
Securities Fraud Investigation Into MoonLake Immunotherapeutics (MLTX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Tickers MLTX
Rosen Law Firm Encourages Brunello Cucinelli S.p.A. Investors to Inquire About Securities Class Action Investigation – BCUCY
From The Rosen Law Firm, P.A.
Via Business Wire
C3.ai 96 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against C3.ai, Inc. - AI
From Kahn Swick & Foti, LLC
Via Business Wire
Tickers AI
Snap 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Snap Inc. - SNAP
From Kahn Swick & Foti, LLC
Via Business Wire
Tickers SNAP
Asteria Announces New Animated Short All Heart From Oscar-Winning Filmmakers Michael Govier & Will McCormack and Executive Producer Natasha Lyonne
From Asteria
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.